Salivary Gland Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma that arises from the major or minor salivary glands. Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma. 
Salivary gland carcinomas most frequently harbor alterations in TP53, NOTCH1, PIK3CA, CDKN2A, and ERBB2 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and NOTCH1 Mutation are the most common alterations in salivary gland carcinoma .
There are 13 clinical trials for salivary gland carcinoma, of which 12 are open and 1 is completed or closed. Of the trials that contain salivary gland carcinoma as an inclusion criterion, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 9 are phase 2 (9 open).
AR, ERBB2, and HER2 are the most frequent gene inclusion criteria for salivary gland carcinoma clinical trials .
Pembrolizumab, carboplatin, and ipilimumab are the most common interventions in salivary gland carcinoma clinical trials.
Significant Genes in Salivary Gland Carcinoma
ERBB2 is altered in 6.96% of salivary gland carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.